Sino Biological Inc. Spotlight

In this interview, we mainly discussed the company philosophy, core business and future development of Sino Biological Inc.

1. What is your company’s mission?

Sino Biological, Inc. is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. Sino Biological helps our customers obtain the best reagents in the needed amounts to accelerate the pace of discovery and improve human health.

2. What products and services do you offer?

Sino Biological, Inc. is a global leader in manufacturing affordable, high-quality biological research reagents, including recombinant proteins, antibodies, and cDNA clones, and comprehensive CRO services worldwide, especially in recombinant protein production and antibody development.

Sino Biological, Inc. offers over 6,000 kinds of recombinant proteins and can produce them in amounts ranging from micrograms to grams. As a dynamic and fast-growing company, Sino Biological has a continuously expanding product line. The company has launched more than 12,000 kinds of antibodies, 28,000 genes, as well as a series of tools and reagents such as ELISA kits, cell culture media, and transfection reagents.

Sino Biological is also dedicated to virology and infectious disease research, and its newly launched ProVirTM virus-based reagent collection is the world’s largest viral antigen bank, carrying over 800 products from 350 strains of viruses. Sino Biological was the first company to produce the SARS-CoV-2 (COVID-19) viral antigens

3. What problems do you solve?

Sino Biological’s products cover a broad range of targets for life science research and drug development, including immunology, cell biology, oncology, neuroscience, stem cell therapy, and virus studies. Compared with other brands, Sino Biological guarantees that scientific research users can obtain higher quality reagents with faster delivery at a lower cost.

4. What are the most innovative tools and technologies that you offer?

Sino Biological, Inc. has a suite of internationally advanced core technologies. The company’s established technology platforms have full-level carrying capacity, with the ability to move research and development from the pilot test phase to full-scale production. The platforms can realize high-throughput and high-efficiency research and production of recombinant protein reagents. Recombinant proteins and monoclonal antibodies are the company's core products.

5. What are your competitive advantages?

Innovation permeates all aspects of Sino Biological’s enterprise, making it one of the largest mainstream suppliers of protein and antibody research tools in the world. Its one-stop shop integrates R&D, production, and sales. Our CRO services, featuring advanced recombinant protein and monoclonal antibody production platforms, enable customers to save time and money so they can focus on new ways to improve human health.

6. Who are your clients?

Sino Biological, Inc. provides a one-stop shop for life science researchers and pharmaceutical companies around the world, serving 20,000 clients globally since 2007, and helping our customers obtain the best reagents and service to make advancements.

7. What new products and services are you developing in 2021?

Sino Biological has developed a high-throughput single B cell sorting and monoclonal antibody (mAb) cloning platform, which is highly efficient in rapidly obtaining specific mAbs with preservation of the natural heavy and light chain pairing. It’s a powerful technique to generate monoclonal antibodies from human and immunized animals. Sino Biological provides single B cell antibody service worldwide, involving single B cell isolation, sequencing, cloning, and in vitro expression.

Sino Biological draws on extensive experience in the field to provide customized anti-idiotype antibodies (anti-ID Abs) development and downstream assay services to support the research involving antibody-drug pharmacokinetics and immunogenicity. Anti-idiotype antibodies can be produced as polyclonal or monoclonal antibodies depending on the needs of the study. Sino Biological develops fit-for-purpose technologies and screening workflows that will drastically enhance the success of the selection of ideal anti-idiotypic antibodies.

Sino Biological is an international reagent supplier, all of Sino Biological’s products are independently developed and produced. Sino Biological will focus on expanding portfolio of products including infection virus antigens, drug targets, and cytokines.

8. Where are your laboratories and offices located?

Sino Biological, Inc. is headquartered in Beijing, China with subsidiaries in the United States and Europe and branches in Shanghai, China

About Sino Biological Inc.

Sino Biological, Inc. is a global leader in manufacturing affordable, high-quality reagents, including recombinant proteins, antibodies and cDNA clones—all in-house. We provide a one-stop shop for researchers and pharmaceutical companies around the world, helping our customers obtain the best reagents in the needed amounts to accelerate the pace of discovery and improve human health.

Sino Biological's core business

Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. All of our products are independently developed and produced. In addition, we offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates. Our product quality control indicators meet rigorous requirements for clinical use samples. It takes only a few weeks for us to produce 1 to 30 grams of purified monoclonal antibody from gene sequencing.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jan 22, 2021 at 4:40 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sino Biological Inc.. (2021, January 22). Sino Biological Inc. Spotlight. News-Medical. Retrieved on April 11, 2021 from https://www.news-medical.net/whitepaper/20210121/Sino-Biological-Inc-Spotlight.aspx.

  • MLA

    Sino Biological Inc.. "Sino Biological Inc. Spotlight". News-Medical. 11 April 2021. <https://www.news-medical.net/whitepaper/20210121/Sino-Biological-Inc-Spotlight.aspx>.

  • Chicago

    Sino Biological Inc.. "Sino Biological Inc. Spotlight". News-Medical. https://www.news-medical.net/whitepaper/20210121/Sino-Biological-Inc-Spotlight.aspx. (accessed April 11, 2021).

  • Harvard

    Sino Biological Inc.. 2021. Sino Biological Inc. Spotlight. News-Medical, viewed 11 April 2021, https://www.news-medical.net/whitepaper/20210121/Sino-Biological-Inc-Spotlight.aspx.

Other White Papers by this Supplier